Stockpolly
Search
Delisting risk
GTBP · NASDAQ · Biotechnology

GT Biopharma (GTBP)

Developer of natural-killer-cell engagers for cancer and autoimmune disease.

$0.2833
At close−0.01 (−1.94%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
333444223635
Research & development111212101101
222222113423
Selling & marketing000000000000
General & administrative020200113003
Other expenses000000000000
Operating income−3−3−3−4−4−4−2−2−3−6−3−5
1010001−2912−1700
Interest income000000000000
Interest expense000000000000
Other non-operating income−10−1000−129−121600
Income before tax−2−3−2−4−3−4−1−308−23−3−5
Net income from continuing operations−2−3−2−4−3−4−1−308−23−3−5
Net income−2−3−2−4−3−4−1−308−23−3−5
EPS, basic−$1.77−$2.15−$1.64−$2.17−$1.53−$1.99−$0.33−$0.55$1.04−$4.97−$0.11−$0.12
EPS, diluted−$1.77−$2.15−$1.64−$2.17−$1.53−$1.99−$0.33−$0.55$1.04−$4.97−$0.11−$0.12
Weighted average shares, basic11122223463039
Weighted average shares, diluted11122223463039
EBITDA−2−31−4−3−4−1−308−21−3−4
Depreciation & amortization003000000000
EBIT−2−3−2−4−3−4−1−308−21−3−4